|
U26-277-2
|
|
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide - TRIlogy-5
|
|
Dr. Swarup Kumar
|
|
The purpose of this study is to compare the effects of the investigational drug called JNJ-79635322 against teclistamab in patients with multiple myeloma after 1 to 3 lines of prior therapy.
|
Cancer - Multiple Myeloma
|
|
|
Check with study contact
|
|
Kristen Grandonico Telephone: Telephone: 860-679-6580. Email: grandonico@uchc.edu
|
|
Enrolling/recruiting.
|